Drug intelligence / Profile preview

AMG 581 + midazolam

Development stage: Unknown
Lead developer: Amgen
Modality: Small Molecules
Administration: Oral, Intravenous, Intramuscular, Intranasal, Rectal

Overview

AMG 581 + midazolam is a combination of two drugs: AMG 581, which is a developmental compound (details such as chemical class and mechanism are not provided in public sources), and midazolam, a short-acting benzodiazepine with anxiolytic, sedative, muscle relaxant, anticonvulsant, hypnotic, and amnesic properties. This combination is not an approved or marketed product, and there is little or no evidence in public databases that this specific combination is being formally developed or used clinically. Midazolam alone is commonly used for sedation, anesthesia, seizure management, and procedural sedation[1][7].

Targets

GABRR (GABA-A receptor subunit rho)

Beyond the preview

Go deeper on AMG 581 + midazolam.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AMG 581 + midazolam.

Explore the full profile